FDA Monthly Preview: Key May Decisions to Watch - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Monthly Preview: Key May Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

  • By

  • Kathryn Wighton

  • April 29, 2026

  • 4 min

Share

  • 1

    The FDA is set to make several key regulatory decisions in May 2026 across neurology, endocrinology, psychiatry, and ophthalmology.

  • 2

    VYVGART has received priority review for treating generalized myasthenia gravis, with a PDUFA date of May 10, 2026.

  • 3

    Afrezza's sBLA for pediatric diabetes treatment has been accepted, targeting a PDUFA date of May 29, 2026.

  • 4

    CTx-1301 for ADHD has an upcoming PDUFA date of May 31, 2026, following positive Phase 3 trial results.

  • 5

    ONS-5010/LYTENAVA is under FDA review after a Complete Response Letter, with feedback expected in May 2026.

Original Source(s)

FDA Monthly Preview: Key May Decisions to Watch

  • by Kathryn Wighton

  • April 29, 2026

Related Content

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.

Language Processing Persists Under Anesthesia

Intraoperative recordings suggested preserved processing of speech and auditory context during unconsciousness.

Preop Cognitive Impairment Tied to TKA Delirium

Older patients with documented cognitive impairment also experienced greater postoperative functional decline following elective total knee arthroplasty